EE9500059A - Asendatud 4-fenüül-6-aminonikotiinhappe derivaatide kasutamine ravimitena - Google Patents

Asendatud 4-fenüül-6-aminonikotiinhappe derivaatide kasutamine ravimitena

Info

Publication number
EE9500059A
EE9500059A EE9500059A EE9500059A EE9500059A EE 9500059 A EE9500059 A EE 9500059A EE 9500059 A EE9500059 A EE 9500059A EE 9500059 A EE9500059 A EE 9500059A EE 9500059 A EE9500059 A EE 9500059A
Authority
EE
Estonia
Prior art keywords
medicaments
phenyl
substituted
acid derivatives
aminonicotinic acid
Prior art date
Application number
EE9500059A
Other languages
English (en)
Estonian (et)
Inventor
Urbahns Klaus
Goldmann Siegfried
Heine Hans-Georg
Junge Bodo
Schohe-Loop Rudolf
Sommermeyer Henning
Glaser Thomas
Wittka Reilinde
De Vry Jean-Marie-Viktor
Original Assignee
Bayer Aktiengesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Aktiengesellschaft filed Critical Bayer Aktiengesellschaft
Publication of EE9500059A publication Critical patent/EE9500059A/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79Acids; Esters
    • C07D213/80Acids; Esters in position 3
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79Acids; Esters
    • C07D213/803Processes of preparation
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/84Nitriles
    • C07D213/85Nitriles in position 3
EE9500059A 1994-08-29 1995-08-28 Asendatud 4-fenüül-6-aminonikotiinhappe derivaatide kasutamine ravimitena EE9500059A (et)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE4430638A DE4430638A1 (de) 1994-08-29 1994-08-29 Verwendung von substituierten 4-Phenyl-6-amino-nicotinsäurederivaten als Arzneimittel

Publications (1)

Publication Number Publication Date
EE9500059A true EE9500059A (et) 1996-04-15

Family

ID=6526833

Family Applications (1)

Application Number Title Priority Date Filing Date
EE9500059A EE9500059A (et) 1994-08-29 1995-08-28 Asendatud 4-fenüül-6-aminonikotiinhappe derivaatide kasutamine ravimitena

Country Status (20)

Country Link
US (1) US5670525A (xx)
EP (1) EP0705820A1 (xx)
JP (1) JPH0867670A (xx)
KR (1) KR960007565A (xx)
CN (1) CN1127114A (xx)
AU (1) AU697552B2 (xx)
CA (1) CA2156961A1 (xx)
CZ (1) CZ219895A3 (xx)
DE (1) DE4430638A1 (xx)
EE (1) EE9500059A (xx)
FI (1) FI954007A (xx)
HU (1) HUT74618A (xx)
IL (1) IL115072A (xx)
NO (1) NO308287B1 (xx)
NZ (1) NZ272851A (xx)
PL (1) PL310145A1 (xx)
RU (1) RU2154635C2 (xx)
SK (1) SK106595A3 (xx)
TW (1) TW419464B (xx)
ZA (1) ZA957187B (xx)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999024830A1 (en) * 1997-11-10 1999-05-20 Bristol-Myers Squibb Company Method for diagnosing alzheimer's disease
DE10059418A1 (de) 2000-11-30 2002-06-20 Aventis Pharma Gmbh Ortho, meta-substituierte Bisarylverbindungen, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament sowie sie enthaltende pharmazeutische Zubereitungen
DE10060807A1 (de) * 2000-12-07 2002-06-20 Aventis Pharma Gmbh Ortho, ortho-substituierte stickstoffhaltige Bisarylverbindungen, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament sowie sie enthaltende pharmazeutische Zubereitungen
DE10110747A1 (de) * 2001-03-07 2002-09-12 Bayer Ag Substituierte 2,6-Diamino-3,5-dicyano-4-aryl-pyridine und ihre Verwendung
DE10115945A1 (de) 2001-03-30 2002-10-02 Bayer Ag Substituierte 2-Carba-3,5-dicyano-4-aryl-6-aminopyridine und ihre Verwendung
US20050075359A1 (en) * 2003-03-14 2005-04-07 Rikako Kono Large conductance calcium-activated K channel opener
AU2006216566A1 (en) * 2005-02-24 2006-08-31 Janssen Pharmaceutica N.V. Novel pyridine derivatives as potassium ion channel openers
DE102006042143A1 (de) * 2006-09-08 2008-03-27 Bayer Healthcare Aktiengesellschaft Neue substituierte Bipyridin-Derivate und ihre Verwendung
DE102006056739A1 (de) * 2006-12-01 2008-06-05 Bayer Healthcare Ag Substituierte 4-Amino-3,5-dicyano-2-thiopyridine und ihre Verwendung
DE102006056740A1 (de) * 2006-12-01 2008-06-05 Bayer Healthcare Ag Cyclisch substituierte 3,5-Dicyano-2-thiopyridine und ihre Verwendung
DE102007035367A1 (de) 2007-07-27 2009-01-29 Bayer Healthcare Ag Substituierte Aryloxazole und ihre Verwendung
DE102007036076A1 (de) 2007-08-01 2009-02-05 Bayer Healthcare Aktiengesellschaft Dipeptoid-Produgs und ihre Verwendung
DE102007061763A1 (de) * 2007-12-20 2009-06-25 Bayer Healthcare Ag Substituierte azabicyclische Verbindungen und ihre Verwendung
DE102007061764A1 (de) * 2007-12-20 2009-06-25 Bayer Healthcare Ag Anellierte Cyanopyridine und ihre Verwendung
DE102008013587A1 (de) * 2008-03-11 2009-09-17 Bayer Schering Pharma Aktiengesellschaft Heteroaryl-substituierte Dicyanopyridine und ihre Verwendung
EP2297104B1 (de) * 2008-05-29 2013-08-07 Bayer Intellectual Property GmbH 2-alkoxy-substituierte dicyanopyridine und ihre verwendung
DE102008062567A1 (de) 2008-12-16 2010-06-17 Bayer Schering Pharma Aktiengesellschaft Dipeptoid-Prodrugs und ihre Verwendung
DE102009006602A1 (de) * 2009-01-29 2010-08-05 Bayer Schering Pharma Aktiengesellschaft Alkylamino-substituierte Dicyanopyridine und deren Aminosäureester-Prodrugs
DE102010030688A1 (de) 2010-06-30 2012-01-05 Bayer Schering Pharma Aktiengesellschaft Substituierte Dicyanopyridine und ihre Verwendung
US20120058983A1 (en) 2010-09-02 2012-03-08 Bayer Pharma Aktiengesellschaft Adenosine A1 agonists for the treatment of glaucoma and ocular hypertension
US9056832B2 (en) * 2010-09-17 2015-06-16 Purdue Pharma L.P. Pyridine compounds and the users thereof

Also Published As

Publication number Publication date
SK106595A3 (en) 1997-01-08
US5670525A (en) 1997-09-23
IL115072A (en) 1999-12-31
CN1127114A (zh) 1996-07-24
NO953367D0 (no) 1995-08-28
CA2156961A1 (en) 1996-03-01
HUT74618A (en) 1997-01-28
KR960007565A (ko) 1996-03-22
PL310145A1 (en) 1996-03-04
HU9502520D0 (en) 1995-10-30
NO953367L (no) 1996-03-01
FI954007A0 (fi) 1995-08-25
TW419464B (en) 2001-01-21
RU2154635C2 (ru) 2000-08-20
AU3020595A (en) 1996-03-14
ZA957187B (en) 1996-04-17
AU697552B2 (en) 1998-10-08
NZ272851A (en) 1997-07-27
IL115072A0 (en) 1995-12-08
EP0705820A1 (de) 1996-04-10
FI954007A (fi) 1996-03-01
JPH0867670A (ja) 1996-03-12
CZ219895A3 (en) 1996-03-13
DE4430638A1 (de) 1996-03-07
NO308287B1 (no) 2000-08-28

Similar Documents

Publication Publication Date Title
BR9510256A (pt) Derivados de ácido 3-aril-tetrônico
EE9500059A (et) Asendatud 4-fenüül-6-aminonikotiinhappe derivaatide kasutamine ravimitena
FI950910A (fi) Rasvahappojohdannaiset
ATE211131T1 (de) Arylsulfonylaminohydroxamsäurederivate
FI942076A (fi) Sappihappojohdannaisia, menetelmä niiden valmistamiseksi ja näiden yhdisteiden käyttö lääkaaineina
EE03426B1 (et) Risperidooni vesilahuselised ravimvormid
FI944800A (fi) Indoli-2-karboksyylihappojohdannaisia
DE59010756D1 (de) Silylierte Benzoesäurederivate
FI98067C (fi) Uusia alkyleenidiammoniumdiklavulanaattijohdannaisia, menetelmä niidenvalmistamiseksi samoin kuin niiden käyttö kalvulaanihapon puhdistamiseksi
FI964193A (fi) Puriinien valmistaminen
NO923580L (no) Substituerte imidazolylpropensyrederivater
FI951388A0 (fi) Substituoidut heterosykliset karboksyylihappoamidiesterit, niiden valmistus ja niiden käyttö lääkeaineina
NO20003105D0 (no) Fenylaminoalkylkarboksylsyre-derivater samt medisinske sammensetninger omfattende slike
IT1273471B (it) Derivati dell'acido kojico
NO20012541D0 (no) Anvendelse av fosfonomaursyrederivater for behandling av infeksjoner
DE69514306D1 (de) Kurzkettige 2-hydroxycarbonsäurederivate von ceramiden
EE200000239A (et) Uued metüleenbisfosfoonhappe derivaadid
DE69527684D1 (de) Herstellung von 3-oxy-5-oxo-6-Heptensäurederivaten
KR950702115A (ko) 디히드로피리딘 유도체의 신규 의약 용도(novel medicinal use of dihydropyridine derivative)
DE69305250D1 (de) Herstellung von Alkandicarbonsäurederivaten
DE69502982T2 (de) Herstellung geschützter Aminothiazolylessigsäurederivate
NO20012540D0 (no) Anvendelse av fosfonomaursyrederivater for behandling av infeksjoner
FI971964A (fi) Menetelmä 1-halo-3-trialkyylisilasnyylibentseenijohdannaisten valmistamiseksi
NO991098D0 (no) FremgangsmÕte for fremstilling av 2-fenyl-3-naftylpropionsyrederivater
FI951385A (fi) Substituoidut heterosykliset karboksyylihappoamidit, niiden valmistus ja niiden käyttö lääkeaineina